CG Labz
Peptide Library / Recovery / Inflammation

KPV Recovery Blend

KPV + BPC-157 Complex

KPV + BPC-157 Recovery Blend Research Protocol

Complete Research Guide 4 min read4 peer-reviewed references

Quickstart Overview

A research blend combining KPV — the C-terminal tripeptide (Lys-Pro-Val) of α-MSH responsible for its anti-inflammatory activity — with BPC-157. KPV is studied in inflammatory bowel disease, dermal inflammation and mast-cell modulation; the blend is used in compounded gut and tissue-recovery models.

Reconstitution
Add 2.0 mL bacteriostatic water per blend vial (see label for mg content)
KPV Literature Range
200–500 mcg per administration
BPC-157 Literature Range
250–500 mcg per administration
Frequency
Once or twice daily
Route (studies)
Subcutaneous; oral KPV used in colitis models
Cycle Length
4–8 weeks

Scientific Data

Molecular Formula
Blend
Molecular Weight
—
Sequence
N/A
Sequence Length
2
CAS
DEMO-CAS
Peptide Family
Blend
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, ≤4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.100 mL
Syringe Units
10.0 U
Doses / Vial
20

Units assume a U-100 insulin syringe (100 units = 1 mL). Check the vial label for the exact mg ratio of KPV to BPC-157; the calculator treats total blend mass.

Frequency: Once to twice daily

Reconstitution Steps

  1. 1Bring vial to room temperature; swab stoppers.
  2. 2Add 2.0 mL bacteriostatic water slowly along the glass.
  3. 3Swirl gently until clear.
  4. 4Label and refrigerate; use within 4 weeks.

Supplies Needed

Planning example for an 8-week protocol at 500 mcg total blend once daily.

Blend Vials (10 mg)
8 weeks ≈ 28 mg ≈ 3 vials
Bacteriostatic Water
One 30 mL vial
Insulin Syringes (U-100)
56
Alcohol Swabs
2 per administration

Protocol Overview

Goal
Model combined anti-inflammatory (KPV) and tissue-repair (BPC-157) pathways in gut and soft-tissue research.
Schedule
Daily for 4–8 weeks.
Dose Range
400–1000 mcg total blend per day.

Dosing Protocol

Start
250 mcg total once daily
Increase
To 500 mcg once or twice daily
Frequency
1–2× daily
Cycle Length
4–8 weeks on, 4 weeks off
Timing
Empty stomach in GI-focused models

Storage Instructions

Lyophilized
−20 °C long term
Reconstituted
2–8 °C, use within 4 weeks
Light
Protect from light

Important Notes

  • KPV is remarkably well tolerated in preclinical models; most adverse signals derive from the BPC-157 component.
  • Oral KPV is absorbed via PepT1 transporters in the colon — the basis of IBD-model efficacy.
  • Blends complicate dose attribution; single-compound controls are preferable in formal study design.

How This Works

KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine production (IL-6, IL-8, TNF-α) in epithelial and immune cells, independent of melanocortin receptor activation. It is transported into colonic cells via PepT1, where it attenuates inflammatory signalling in colitis models, and it stabilises mast cells in dermal inflammation. BPC-157 complements this by promoting angiogenesis, fibroblast migration and mucosal integrity. The blend targets inflammation suppression and tissue restoration in parallel.

Potential Benefits & Side Effects

Reported in research
  • Potent NF-κB-mediated anti-inflammatory activity (KPV)
  • Reduced colitis severity in DSS and TNBS mouse models
  • Mast-cell stabilisation and dermal anti-inflammatory effects
  • Tissue repair and mucosal protection (BPC-157)
  • Antimicrobial activity reported for KPV against S. aureus and C. albicans
Possible considerations
  • Mild injection-site irritation
  • Nausea or light-headedness (BPC-157 component)
  • Limited combined safety data

Lifestyle Factors

  • Low-inflammatory dietary patterns are standard controls in GI research
  • Fibre and fermented foods support mucosal models
  • Avoid NSAIDs unless protocol-specific

Injection Technique

  1. 1Subcutaneous abdominal, 45–90°.
  2. 2Rotate sites; inject slowly.
  3. 3Dispose of syringes in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Gastroenterology
    Dalmasso G. et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
    View Source
  2. [2] Journal of Immunology
    Brzoska T. et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo.
    View Source
  3. [3] Peptides
    Kannengiesser K. et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
    View Source
  4. [4] Journal of Physiology & Pharmacology
    Sikiric P. et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
    View Source